Greenwave Tech Solns Bolsa (NASDAQ: GWAV)

Últimas noticias sobre Greenwave Tech Solns (NASDAQ:GWAV) Bolsa

Greenwave Tech Solns

Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia and North Carolina. At these facilities, the company is involved in collecting, classifying, and processing raw scrap metal (ferrous and nonferrous) for recycling. The company's products are selling ferrous metal, which is used in the recycling and production of finished steel. It is categorized into heavy melting steel, plate and structural, and shredded scrap. and it also processes nonferrous metals such as aluminum, copper, stainless steel, nickel, brass, titanium, alloys, and mixed metal products.

Greenwave Technology Solutions, Inc. - Common Stock

Greenwave Technology Solutions Inc

AptarGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.27 by 19.69 percent. The company reported quarterly sales of $848.09 million which missed the analyst consensus estimate of $852.26 million by 0.49 percent. This is a 1.15 percent increase over sales of $838.48 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

AptarGroup Q4 2024 Adj EPS $1.52 Beats $1.27 Estimate, Sales $848.09M Miss $852.26M Estimate

Songyee is the Founder and Managing Partner of Principal Venture Partners and former President for NCSoft Corporation, a gaming developer.&nbsp;

Management

HP Inc. Names Songyee Yoon To Board, Effective Immediately

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 4.57% on an annualized basis producing an average annual return of 15.92%. Currently, Caterpillar has a market capitalization of $176.42 billion. 
Buying $1000 In CAT: If an investor had bought $1000 of CAT stock 10 years ago, it would be worth $4,355.78 today based on a price of $365.40 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738880146_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) shares are diving in Thursday&#8217;s after-hours session after the company reported second-quarter financial results. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/b43544675/bill-reports-second-quarter-fiscal-year-2025-financial-results">of the report</a>.
<ul>
<li>Q2 Revenue: $362.55 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $360.23 million</li>
</ul>
<ul>
<li>Q2 Adjusted EPS: 56 cents, versus estimates of 46 cents</li>
</ul>
Total revenue increased 14% year-over-year, while core revenue climbed 16%. Core revenue consists of subscription and transaction fees. The company ended the quarter with $1.57 billion in cash and cash equivalents. 
&#8220;We delivered strong financial results and innovated at a rapid pace as we executed on our vision to be the de facto intelligent financial operations platform for SMBs,&#8221; said René Lacerte, founder and CEO of Bill Holdings.
&#8220;We are leveraging our leadership position to empower small and mid-sized businesses and the partners that we serve, and we are extending our lead by expanding the depth and breadth of our platform and diverse distribution ecosystem. Today, more than 480,000 businesses rely on BILL to manage their day-to-day financial workflow. We are moving fast to address a vast market opportunity to transform the financial operations for millions of SMBs.&#8221;
See Also: <a href="https://www.benzinga.com/25/02/43545590/amazoncom-q4-earnings-highlights-revenue-beat-eps-beat-most-successful-holiday-shopping-season-in-company-history">Amazon.com Q4 Earnings: Jassy Highlights &#8216;Successful&#8217; Holiday Season, Q1 Guidance Disappoints Investors</a>
What&#8217;s Next: Bill Holdings expects third-quarter revenue of $352.5 million to $357.5 million versus estimates of $360.36 million. The company sees third-quarter adjusted earnings in the range of 35 cents to 38 cents per share versus estimates of 34 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Bill Holdings also raised its full-year outlook. The company expects full-year revenue of $1.45 billion to $1.47 billion versus estimates of $1.46 billion. Bill expects full-year adjusted earnings to be between $1.87 and $1.97 per share. 
Management is currently discussing the quarter on a conference call that started at 4:30 p.m. ET.
BILL Price Action: <a href="http://benzinga.com/quote/bill">Bill Holdings shares</a> were down 31.76% after hours, trading at $65.75 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Guidance

After-Hours Center

Movers

BILL

Bill Holdings Stock Plunges On Q2 Earnings: What's Going On?

POST

Post Holdings Revises FY25 Adjusted EBITDA Guidance From $1.41B - $1.46B To $1.42B - $1.46B

Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) reported quarterly earnings of $3.20 per share which beat the analyst consensus estimate of $1.25 by 156 percent. This is a 10.61 percent decrease over earnings of $3.58 per share from the same period last year. The company reported quarterly sales of $151.60 million which beat the analyst consensus estimate of $106.67 million by 42.12 percent. This is a 46.33 percent increase over sales of $103.60 million the same period last year.

Centrus Energy Q4 Adj ESP $3.20 Beats $1.25 Estimate, Sales $151.60M Beat $106.67M Estimate

SILV

SilverCrest Securityholders Approve Plan Of Arrangement With Coeur Mining

Fourth Quarter 2024 Select Preliminary Estimated Financial Results:
<ul>
<li>Net income range of approximately $(107) to $(101) million</li>
<li>Adjusted EBITDA range of approximately $(4.5) to $(3.5) million</li>
<li>Cash and cash equivalents of approximately $572 million plus another $26 million of short-term deposits included in Other current assets</li>
</ul>

WBTN

WEBTOON Reports Preliminary Q4 Total Revenue Of $351M, Revenue On Constant Currency Basis Of $367M; Est $356.09M

Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) reported its fourth-quarter financial results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/02/b43545041/cloudflare-announces-fourth-quarter-and-fiscal-year-2024-financial-results">figures from the quarter.&nbsp;</a>
The Details: Cloudflare reported quarterly earnings of 19 cents per share, which beat the analyst consensus estimate of 18 cents. Quarterly revenue came in at $459.9 million which beat the analyst consensus estimate of $452.09 million and is an increase over sales of $362.47 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
&#8220;We had a very strong end of 2024. We saw record growth in our largest customers, those that spend more than $1 million with Cloudflare per year—closing the year with 173. We added 55 of those customers in 2024, and more than half of these new additions came in during fourth quarter alone,&#8221; said Matthew Prince, CEO of Cloudflare. 
&#8220;I&#8217;m proud of how our team continued to deliver ground-breaking innovation, especially in AI, and remained focused on delivering real ROI for customers. We drove the record results in the fourth quarter while ensuring we&#8217;re well-positioned to capture the demand we see lined up in 2025 to reaccelerate Cloudflare&#8217;s growth,&#8221; added Prince. 
Outlook:&nbsp;Cloudflare sees first-quarter adjusted earnings of 16 cents and revenue in a range of $468 million to $469 million. The company expects fiscal 2025 earnings of between 79 cents and 80 cents and revenue in a range of $2.09 billion to $2.094 billion. 
NET Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Cloudflare shares are up 7.41% after hours at $152 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Image: Shutterstock

Tech

Cloudflare Shares Gain After Strong Q4 Results: Details

Minerals Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) reported quarterly earnings of $1.50 per share which beat the analyst consensus estimate of $1.39 by 7.91 percent. This is a 17.19 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $518.10 million which missed the analyst consensus estimate of $523.00 million by 0.94 percent. This is a 1.22 percent decrease over sales of $524.50 million the same period last year.

Minerals Technologies Q4 2024 Adj EPS $1.50 Beats $1.39 Estimate, Sales $518.10M Miss $523.00M Estimate

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $258.75, accompanied by a high estimate of $265.00 and a low estimate of $240.00. This current average has increased by 0.49% from the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879437_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Steris's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 7.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Steris

In the preceding three months, 6 analysts have released ratings for StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.17, a high estimate of $19.00, and a low estimate of $9.00. Highlighting a 23.3% decrease, the current average has fallen from the previous average price target of $17.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879423_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive StoneCo is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tito Labarta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Gustavo Schroden</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yuri Fernandes</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to StoneCo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of StoneCo compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of StoneCo's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of StoneCo's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STNE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on StoneCo analyst ratings.</a>
<h2>Unveiling the Story Behind StoneCo</h2>
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs great solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services offers payments, digital banking, and credit solutions, focusing Ton solution mainly on micro-merchants, and Stone solution on SMBs. In Software, it offers POS and ERP solutions for different retail and services verticals, Customer Relationship Management, engagement tools, e-commerce, and Order Management System solutions, among others.
<h3>StoneCo's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: StoneCo displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.82%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: StoneCo's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.8%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): StoneCo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.55%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): StoneCo's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.66.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STNE

Breaking Down StoneCo: 6 Analysts Share Their Views

Post Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) reported quarterly earnings of $1.73 per share which beat the analyst consensus estimate of $1.51 by 14.57 percent. This is a 2.37 percent increase over earnings of $1.69 per share from the same period last year. The company reported quarterly sales of $1.98 billion which missed the analyst consensus estimate of $1.99 billion by 0.71 percent. This is a 0.46 percent increase over sales of $1.97 billion the same period last year.

Post Hldgs Q1 2025 Adj EPS $1.73 Beats $1.51 Estimate, Sales $1.98B Miss $1.99B Estimate

6 analysts have shared their evaluations of Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.68, a high estimate of $5.50, and a low estimate of $3.00. Highlighting a 20.14% decrease, the current average has fallen from the previous average price target of $5.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879411_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sight Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.50</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.60</td>
<td>$5.80</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sight Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sight Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sight Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Sight Sciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SGHT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sight Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Sight Sciences</h2>
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
<h3>Sight Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sight Sciences's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 0.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sight Sciences's net margin is impressive, surpassing industry averages. With a net margin of -54.9%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sight Sciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.26%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sight Sciences's ROA excels beyond industry benchmarks, reaching -7.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Sight Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SGHT

What 6 Analyst Ratings Have To Say About Sight Sciences

4 analysts have shared their evaluations of LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.0, with a high estimate of $45.00 and a low estimate of $35.00. This current average reflects an increase of 5.26% from the previous average price target of $38.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879395_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive LiveRamp Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stan Zlotsky</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Stan Zlotsky</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to LiveRamp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of LiveRamp Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of LiveRamp Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of LiveRamp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RAMP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LiveRamp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind LiveRamp Holdings</h2>
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
<h3>Unraveling the Financial Story of LiveRamp Holdings</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining LiveRamp Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.02% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.93%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): LiveRamp Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): LiveRamp Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RAMP

4 Analysts Assess LiveRamp Holdings: What You Need To Know

4 analysts have expressed a variety of opinions on Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $23.62, a high estimate of $24.50, and a low estimate of $23.00. This current average has increased by 1.24% from the previous average price target of $23.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879384_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Ares Capital among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Melissa Wedel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.50</td>
<td>$23.00</td>
</tr>
<tr>
<td>Timothy O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Timothy O'Shea</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ares Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ares Capital compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ares Capital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ares Capital's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ares Capital analyst ratings.</a>
<h2>Discovering Ares Capital: A Closer Look</h2>
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
<h3>Ares Capital: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Ares Capital faced challenges, resulting in a decline of approximately -18.18% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Ares Capital's net margin is impressive, surpassing industry averages. With a net margin of 91.2%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ares Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.13%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ares Capital's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.48%, the company showcases efficient use of assets and strong financial health.
Debt Management: Ares Capital's debt-to-equity ratio is below the industry average. With a ratio of 1.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCC

Analyst Expectations For Ares Capital's Future

The dividend is payable on March 31, 2025, to shareholders of record on March 14, 2025.
 &nbsp;

Dividends

ALLE

Allegion Boosts Quarterly Dividend By 6% From $0.48 To $0.51 Per Share

Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Recursion Pharmaceuticals, revealing an average target of $10.75, a high estimate of $11.00, and a low estimate of $10.00. A 4.44% drop is evident in the current average compared to the previous average price target of $11.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879357_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Recursion Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Recursion Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Recursion Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Recursion Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Recursion Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RXRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Recursion Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Recursion Pharmaceuticals Better</h2>
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
<h3>Recursion Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Recursion Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 158.19%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Recursion Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -367.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Recursion Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -17.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Recursion Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.76%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RXRX

Where Recursion Pharmaceuticals Stands With Analysts

Boehm will succeed Walter P. Glazer, Jr., who in August 2024 announced his plans to retire as CEO and President.&nbsp;

ESCA

Escalade Names Armin Boehm As CEO And President, Effective April 1, 2025

Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) has outperformed the market over the past 5 years by 9.67% on an annualized basis producing an average annual return of 22.25%. Currently, Deere has a market capitalization of $126.64 billion. 
Buying $100 In DE: If an investor had bought $100 of DE stock 5 years ago, it would be worth $276.38 today based on a price of $464.98 for DE at the time of writing.
<h3>Deere's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738879226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Deere 5 Years Ago Would Be Worth Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwave Tech Solns (NASDAQ:<a href="https://investorplace.com/stock-quotes/gwav-stock-quote/">GWAV</a>) just reported results for the second quarter of 2024.<ul><li>Greenwave Tech Solns reported earnings per share of -$8.43.</li><li>The company reported revenue of $7.88 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/gwav-stock-earnings-greenwave-tech-solns-for-q2-of-2024/">GWAV Stock Earnings: Greenwave Tech Solns Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GWAV Stock Earnings: Greenwave Tech Solns Reported Results for Q2 2024

Greenwave Technology (GWAV) Solutions announces its exclusive contract win with the City of Virginia Beach. Under this strategic agreement, Greenwa...

Greenwave Technology wins municipal contract with Virginia Beach

Greenwave Technology Solutions ( ($GWAV) ) has shared an update. On January 28, 2025, Greenwave Technology Solutions, Inc. expanded its Board of Di...

Greenwave Technology Expands Board, Appoints New Director

Greenwave Technology (GWAV) said it is primed for significant revenue acceleration following President Trump's announcement of sweeping tariffs on ...

Greenwave Technology says primed for revenue acceleration after tariffs

Greenwave Technology (GWAV) is raising revenue guidance to $47M-$50M for FY 2025 following President Trump's announcement of sweeping tariffs on st...

Greenwave Technology raises FY25 revenue view to $47M-$50M

GWAV

Screenshot 2024-06-25 at 5.25.38 PM

Movers & Shakers

With Enough Cash In The Coffers, Greenwave Is Putting Its Growth Plans To Work

Screenshot 2024-05-09 at 8.41.34 PM

Markets

Greenwave Technology Shores Up Balance Sheet With Debt-for-Equity Swap, Expects To Process Record Volumes Of Steel And Copper With 2024 Revenues Exceeding $40 Million

Comments

Greenwave Tech Solns

Noticias

Últimas noticias sobre Greenwave Tech Solns (NASDAQ:GWAV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL